PLASTIG » Luxembourg Institute of Health


Tackling tumour heterogeneity and PLASTIcity as resistance mechanisms in Glioblastoma

TRANSCAN3: Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy

The PLASTIG consortium brings together the complementary expertise of four teams from four EU member states with interdisciplinary focus and complementary competences, including basic and clinical research teams, bioinformatics experts and two academic hospital organizations.

PLASTIG will examine resistance to treatment in glioblastoma, the most deadly of brain tumours. Glioblastoma is currently incurable and most patients die within just over a year. Only 5.7% of patients survive longer than 5 years after diagnosis, making it one of the deadliest tumour types. Since 2005, no novel treatment has emerged.